Results 181 to 190 of about 38,272 (314)

Cardio-renal Effect of Dapagliflozin AND Dapagliflozin- Saxagliptin combination on CD34+ve Hematopoietic Stem Cells (HSCs) and Podocyte specific markers in Type 2 Diabetes (T2DM) subjects: a randomized trial. [PDF]

Seshagiri Rao Nandula, Arad Jain, Sabyasachi Sen   +2 more
openalex   +1 more source

Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists for incident dementia: A retrospective multicohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1443-1452, February 2026.
Abstract Objective This study provides real‐world evidence on the comparative effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) regarding the risk of incident dementia in adults with type 2 diabetes mellitus (T2DM).
Filippos Anagnostakis, Michail Kokkorakis, Shrihari Nagarajan, Georgia Anastasiou, Christos S. Mantzoros   +4 more
wiley   +1 more source

Dapagliflozin effect on anemia outcomes in patients with diabetes and CKD

Future Journal of Pharmaceutical Sciences
Background Anemia is a prevalent complication in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), contributing to adverse clinical outcomes.
Ramy Ibrahim Elwaraky, Amira B. Kassem, Ahmed Fathi Elkeraie, Gamal Abdelhay Omran, Noha A. El‑Bassiouny   +4 more
doaj   +1 more source

Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes

, 2012
Edward C. Chao
openalex   +2 more sources

Dapagliflozin Regulates Cardiac Metabolic Remodeling Partially via Uncoupling Protein 3 in a Nondiabetic Thoracic Aortic Constriction-Induced Mouse Model

, 2021
Liwen Bao, Rongchen Liu, Fangying Yan, Hui-Hua Fan, Guoqian Huang, Xiufang Gao, Kun Xie, Yong Li, Haiming Shi   +8 more
openalex   +1 more source

Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway

Diabetology & Metabolic Syndrome
Diabetic nephropathy (DN), one of the more prevalent microvascular complications in patients diagnosed with diabetes mellitus, is attributed as the main cause of end-stage renal disease (ESRD).
Jingshu Sun, Xinyu Zhang, Si-ming Wang, Dandan Chen, Jianqiang Shu, Nannan Chong, Qinglian Wang, Ying Xu   +7 more
semanticscholar   +1 more source

Dapagliflozin improves Myocardial Flow Reserve in patients with Type 2 Diabetes: the DAPAHEART Trial [PDF]

, 2022
D D'Amario, Lucia Leccisotti, Francesca Cinti, Gian Pio Sorice, Margherita Lorusso, M A Guzzardi, Teresa Mezza, Camilla Cocchi, Umberto Capece, Luca Indovina, Pietro Manuel Ferraro, Patricia Iozzo, Alessandro Giordano, Andrea Giaccari, Filippo Crea   +14 more
openalex   +1 more source

Empagliflozin does not prevent progression of Dent's disease type 1 in a mouse model

Experimental Physiology, Volume 111, Issue 2, Page 517-526, 1 February 2026.
Abstract Dent's disease is a rare inherited renal disorder characterized by generalized proximal tubule dysfunction with low molecular weight proteinuria, hypercalciuria, and urinary loss of other solutes. The disease is progressive and leads to chronic kidney disease.
Elise de Combiens, Nadia Frachon, Yohan Bignon, Marc Fila, Clément Brossard, Perrine Frère, Stéphane Lourdel   +6 more
wiley   +1 more source

Dapagliflozin and euglycaemic diabetic ketoacidosis – ‘But doctor my sugars were normal!’ [PDF]

, 2022
K. Watters, Veronica Greener, Akaterini Theodoraki, Edson Nogueira, Kevin Shotliff   +4 more
openalex   +1 more source

Pharmacoeconomics of dapagliflozin in patients with type 2 diabetes mellitus with inadequate glycemic control

Качественная клиническая практика, 2018
Objectives. To evaluate the cost-effectiveness of dapagliflozin in combination with metformin in the treatment T2DM in comparison with glimepiride and sitagliptin also combined with metformin. Methods.
S. K. Zyryanov, M. F. Kalashnikova, D. Yu., E. V. Afanasyeva   +3 more
doaj